Picture of GridAI Technologies logo

GRDX GridAI Technologies Share Price

0.000.00%
us flag iconLast trade - 00:00
TechnologySpeculativeMicro CapTurnaround

Momentum

Relative Strength (%)
1m-24.64%
3m-9.57%
6m+76.62%
1yr+38.59%
Volume Change (%)
10d/3m-94.92%
Price vs... (%)
52w High-49.66%
50d MA-21.09%
200d MA+28.47%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-3.64%
Return on Equity-19.1%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202531st Dec 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of GridAI Technologies EPS forecast chart

Profile Summary

GridAI Technologies Corp., formerly Entero Therapeutics, Inc., offers a grid-edge, artificial intelligence (AI)-driven software and control platform that enables utilities, retail energy providers, and large power users to dynamically manage load and distributed energy resources, including battery energy storage systems. It applies real-time AI scheduling and optimization to orchestrate devices, fleets, and grid-scale assets. The Company also focuses on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Directors

Last Annual
December 31st, 2024
Last Interim
September 30th, 2025
Incorporated
January 30th, 2014
Public Since
October 11th, 2016
No. of Shareholders
85
No. of Employees
2
Sector
Software & IT Services
Industry
Technology
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
3,361,903

GRDX Share Price Performance

Upcoming Events for GRDX

Q4 2025 Entero Therapeutics Inc Earnings Release

Q1 2026 Entero Therapeutics Inc Earnings Release

Similar to GRDX

Picture of 36Kr Holdings logo

36Kr Holdings

us flag iconNASDAQ Capital Market

Picture of 3 E Network Technology logo

3 E Network Technology

us flag iconNASDAQ Capital Market

Picture of A2Z Cust2mate Solutions logo

A2Z Cust2mate Solutions

us flag iconNASDAQ Capital Market

Picture of Abits logo

Abits

us flag iconNASDAQ Capital Market

Picture of Acorn Energy logo

Acorn Energy

us flag iconNASDAQ Capital Market

FAQ